FF-10850
Merkel Cell Carcinoma
Phase 1Active
Key Facts
About FUJIFILM Pharma
FUJIFILM Pharmaceuticals U.S.A., Inc., founded in 2004, is a U.S.-based subsidiary of FUJIFILM Corporation that operates a hybrid business model combining proprietary drug development with a specialized CDMO service. Its core technology platform centers on advanced drug delivery systems, including liposomes and LNPs, which it applies to its internal pipeline of oncology candidates and offers as a service to external partners. The company is advancing several clinical-stage assets, has a recently approved antiviral, and is positioned at the intersection of the growing precision medicine and advanced drug delivery markets.
View full company profileTherapeutic Areas
Other Merkel Cell Carcinoma Drugs
| Drug | Company | Phase |
|---|---|---|
| Navtemadlin (KRT-232) | Kartos Therapeutics | Phase 1/Phase 2 |
| Zynyz (retifanlimab) | Incyte | Marketed |